Now to the important question as to safety of this new class of ‘vaccines’, which are still in their experimental phase of development. The experiment will in fact not finish until 2023. If the ‘vaccines’ are of limited efficacy their safety profile must be as near perfect as any medicine can be since they are being given to healthy people who
might become infected. Based on the strategy outlined above you would predict that the spike protein being produced by the gene-based ‘vaccine’ as having a toxicology profile not dissimilar to what is seen when infected by the virus. And indeed, that’s just what the data tell us. The side-effect reporting systems in the USA and U.K. show unequivocally that these “vaccines” are
an order of magnitude greater of adverse effects than conventional vaccines. Qualitatively the side effect profile is consistent with what we might expect from our knowledge of the biological (pharmacology and toxicology) properties of the spike protein. To claim that the side effects are rare and mild is highly misleading. They are indeed what one might expect to see in sensitive patients.
Then there is the crucial question of what we cannot possibly know at this point – that is of their long-term safety. Again, there are good scientific reasons why these injections might interfere with other vital body systems. It is not good enough to dismiss them as theoretical scaremongering.
It is down to the manufacturer and regulatory authorities to address these issues experimentally and to demonstrate there are no reasons to be concerned. In my view, all the regulatory authorities around the world, including our own MHRA, have failed the general public who would expect that they question every aspect of the safety of medicines, especially when it comes down to the assessment of medicines designed not to treat disease but to prevent disease in otherwise healthy people...
It seems to me that the regulatory authorities may have considered this new class of medicine as a vaccine and followed the toxicology guidelines for conventional vaccines. But as discussed above,
they are not vaccines in the conventional sense. They are injections of a laboratory synthesised gene sequence – what in previous decades we would have called a new chemical entity (NCE). Furthermore, they are being given, not as a single dose, but because of their limited efficacy as repeated injections – called boosters. On the hoof, it seems, it is decided that extra doses must be given. How can this possibly be unless supported by the appropriate safety studies? And how convenient for the worldwide authorities regulating the approval of new medicines that the Centers for Disease Control (CDC) in the USA modified the definitions of vaccine and vaccination – to allow for the new “ways in which vaccines can be administered” – to embrace this new technology that would be previously classed as an NCE. Sorry, but simply changing the definition of the term vaccine to fit the properties of these novel injections doesn’t obviate the need to conduct the appropriate studies by which their safety can properly be assessed. That is why I use the term vaccine in quotation marks or simply describe them as injections.
But have we been blinded and duped by technology and lost sight of the end game of providing safe and effective medicines? Was it a judicious use of the PCR, rapid antigen test technology and information APP technology to drive the test and trace fiasco? Was the gene technology ready to be used in a mass world-wide vaccination programme without a thorough examination of the potential problems of short- and long-term safety of this previously untested technology?
In my view, technocracy has trumped the sound principles, established over decades and centuries, of basic medical practice, immunology, virology, pharmaceutical sciences and public health generally. In the process, political democracy, personal freedoms, free speech and choice have been dangerously sidelined and even censored.
John D. Flack B. Pharm. Ph.D. is a retired Pharmaceutical Research and Development Scientist.